Pacific Biosciences cut its 2026 revenue guidance after missing Q2 expectations and appointed a replacement CEO, underscoring pressure on performance and execution in long-read sequencing. The company also announced availability of SPRQ-Nx chemistry for its Vega platform, combined with a software update intended to reduce cost per gigabase by about 40%. The move reflects a dual strategy: immediate financial course correction paired with technical cost-down improvements to strengthen unit economics for customers. Sequencing vendor competition increasingly turns on throughput and cost, with chemistry and software integration becoming decisive. Separately, PacBio leadership turnover adds near-term uncertainty for product roadmaps, partner commitments, and customer purchasing behavior as markets weigh whether the chemistry upgrade can quickly offset revenue headwinds.